Intracortical Visual Prosthesis for Vision Loss

(ICVP Trial)

This trial aims to determine if a special device can create artificial vision for individuals who are completely blind. Researchers implant the device, a wireless floating microelectrode array, in the brain's vision processing areas to assess its ability to help participants "see" through electrical signals. It targets those with no light perception in both eyes, who had normal vision for at least the first ten years of life, and who have adjusted to their blindness for at least a year.

As an unphased trial, this study provides a unique opportunity for participants to contribute to groundbreaking research that could revolutionize vision restoration.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Wireless Floating Microelectrode Array (WFMA) is generally well-tolerated. Early studies with the first five participants found that patients accepted the device and successfully used it to see images without major issues.

Evidence also indicates that the WFMA can safely assist the brain in creating vision. It bypasses damaged parts of the eye and directly stimulates the visual cortex, the brain region responsible for sight. The technology uses specific frequencies and methods to ensure safety and avoid harming the brain.

Unlike other treatments for blindness that often rely on external devices or medications, the WFMA Cortical Visual Prosthesis is a game-changer because it involves directly implanting a wireless microelectrode array into the brain's vision processing areas. This innovative approach aims to create artificial vision by stimulating the brain's visual cortex, offering the potential for more natural and direct visual experiences. Researchers are excited about this treatment because it bypasses damaged optic nerves and eyes, directly interacting with the brain, which might provide vision possibilities that current therapies can't offer.

Research has shown that the Wireless Floating Microelectrode Array (WFMA), which participants in this trial will receive, can help create artificial vision. Studies indicate that it bypasses damaged parts of the eye, such as the retina and optic nerves, and directly stimulates the brain's vision areas. Early results from the first five participants showed that the device was well tolerated and could create visual experiences. The WFMA uses wireless technology to connect with the brain, making it a promising tool for helping people with blindness see again. Overall, early findings are encouraging and suggest the device could restore a useful level of vision.¹²³⁴⁶